STAFF BOARD
Article
CHAIRMAN
Maruxa Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Tomás Casasín Edo
MARKETING MANAGER
EDITORIAL BOARD
María B. Badía Tahull
Lluís Campins Bernadas
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 23 - Issue 3, July-September 2021
ORIGINAL
SWITCHING TO GUSELKUMAB IN MODERATE-TO-SEVERE PSORIASIS: ROLE OF PATIENT-REPORTED OUTCOMES AND HOSPITAL PHARMACISTS
MERCADAL ORFILA GABRIEL, ESCRIVÁ SANCHO EUGENIA, BLASCO MASCARÓ IGNACIO, LIÑANA GRANELL CARLA, ROMERO DEL BARCO ROCÍO


Objective: The study objective was to assess the value of patient-reported outcomes
(PRO) in guiding the switching of biological agents in patients with moderate-to-severe
psoriasis attending hospital pharmacy clinics.
Method: At the suggestion of hospital pharmacists, 45 patients completed the Psoriasis Symptoms and Signs Diary with seven-day recall (PSSD_7D). Those with a PSSD_7D score of ≥20 were referred to the dermatology service for switching to guselkumab. The PSSD_7D score was reassessed after one, six and 12 months of guselkumab therapy.

Results: Fourteen patients had a PSSD_7D score of ≥20. All were accepted for switching to guselkumab at standard doses. An improvement in the mean PSSD_7D
score was already clear within the first month of guselkumab therapy. After 12 months,
the score was 83.4% lower than at baseline.

Conclusions: A PRO instrument could be useful in clinical practice to guide biological therapy in patients with psoriasis.

DRUG SWITCHING – GUSELKUMAB – PATIENT-REPORTED OUTCOMES – PSORIASIS



Fill out the form below to buy this article

Name and surname:

DNI/NIF ID/VAT IDENTIFICATION No.:

Contact Email:

Phone:

Address:

Zip code:

City:

Province:

Country:

*I have read and accept the privacy policy
Price : 30,25